A Review of the Medicor Cancer Clinic DCA Efficacy Data, December 2007

Summary of Important Points

For Medicor's full report, go to the Medicor Cancer Clinic site.

What I have tried to do here is look at their data a little differently.

118 patients have started or used DCA at Medicor for more than 4 weeks.
32 have been with them for less than 4 weeks and were excluded as being on DCA for too short a time.

86 patients were included for review.
Of this group, 24 died within 4 weeks of starting DCA and 9 stopped taking DCA. This left 53 patients for proper evaluation.

Of these 53 patients, 36 had positive results. (Note the numbers given here were provided graciously by Medicor to us so we could analyze using "exclusive" categories):

6 had tumor reduction
4 had reduced tumor markers
3 had improvements in blood chemistry
9 had symptom improvements
14 had tumor stabilization

11 had tumor progression (the cancers got worse)
In 6 patients tumor effects were not determinable either way.

In the biggest picture of all the 87 patients in the review, including those with extremely severe cancer, DCA helped 36 of them, or 41 percent.

Of the patients who were on could stay on DCA for a least one month, the overall response rate was 67 percent.

Significantly, two thirds of the patients reported no side effects.

Let us look at how this DCA response rate compares to standard chemotherapy:

This table is from "Fast Fact and Concept #099: Chemotherapy: Response and Survival Data "

"Response rates in the treatment arms for NSCLC ranged from 7% to 42%" from Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? )